Stryker Co. (NYSE:SYK) Shares Acquired by L & S Advisors Inc

L & S Advisors Inc increased its holdings in shares of Stryker Co. (NYSE:SYK) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,899 shares of the medical technology company’s stock after acquiring an additional 180 shares during the period. L & S Advisors Inc’s holdings in Stryker were worth $2,484,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. J. W. Coons Advisors LLC increased its holdings in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its holdings in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after buying an additional 27 shares in the last quarter. Opal Wealth Advisors LLC lifted its position in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after acquiring an additional 28 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock worth $507,000 after acquiring an additional 28 shares in the last quarter. Finally, Alhambra Investment Management LLC grew its holdings in shares of Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after acquiring an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SYK. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Truist Financial increased their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Finally, Barclays lifted their price objective on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $421.90.

Stryker Price Performance

SYK stock opened at $364.38 on Friday. The stock has a 50-day moving average price of $384.08 and a two-hundred day moving average price of $374.32. The company has a market cap of $139.08 billion, a PE ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s payout ratio is 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.